Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research, development and patents	$ 1,735,735	$ 2,564,969	$ 3,212,411	$ 4,676,965
General and administrative	1,564,295	1,524,966	3,050,862	2,822,982
Total operating expenses	3,300,030	4,089,935	6,263,273	7,499,947
Operating loss	(3,300,030)	(4,089,935)	(6,263,273)	(7,499,947)
Interest income	451,420	91,275	960,466	128,614
Other expense	(23,210)	(30,338)	(486,517)	(44,082)
Net loss applicable to common stockholders	$ (2,871,820)	$ (4,028,998)	$ (5,789,324)	$ (7,415,415)
Basic net loss per common share	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.15)
Diluted net loss per common share	$ (0.06)	$ (0.08)	$ (0.12)	$ (0.15)
Shares used to compute basic net loss per common share	49,046,246	49,045,587	49,046,246	49,044,423
Shares used to compute diluted net loss per common share	49,046,246	49,045,587	49,046,246	49,044,423
Net loss applicable to common stockholders	$ (2,871,820)	$ (4,028,998)	$ (5,789,324)	$ (7,415,415)
Other comprehensive loss, net of tax:
Foreign currency translation adjustments	(4,213)	(11,980)	(5,755)	(19,415)
Comprehensive loss	$ (2,876,033)	$ (4,040,978)	$ (5,795,079)	$ (7,434,830)